Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ChemoMetec

BATS-CHIXE:CHEMMC
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CHEMMC
BATS-CHIXE
DKK4B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

ChemoMetec A/S designs, develops, and produces instruments for a range of applications in cell counting and evaluation in Denmark and internationally. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • ChemoMetec has significant price volatility in the past 3 months.
CHEMMC Share Price and Events
7 Day Returns
25.4%
BATS-CHIXE:CHEMMC
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
67.2%
BATS-CHIXE:CHEMMC
-15.8%
GB Life Sciences
-23%
GB Market
CHEMMC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ChemoMetec (CHEMMC) 25.4% -5.2% 10.5% 67.2% 558% -
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • CHEMMC outperformed the Life Sciences industry which returned -15.8% over the past year.
  • CHEMMC outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
CHEMMC
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for ChemoMetec's competitors could be found in our database.

CHEMMC Value

 Is ChemoMetec undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ChemoMetec to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ChemoMetec.

BATS-CHIXE:CHEMMC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:CHEMMC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.029 (1 + (1- 22%) (0.08%))
1.02
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.02 * 5.44%)
6.08%

Discounted Cash Flow Calculation for BATS-CHIXE:CHEMMC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ChemoMetec is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:CHEMMC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (DKK, Millions) Source Present Value
Discounted (@ 6.08%)
2020 41.30 Est @ 24.49% 38.93
2021 48.44 Est @ 17.3% 43.05
2022 54.39 Est @ 12.27% 45.56
2023 59.14 Est @ 8.75% 46.71
2024 62.86 Est @ 6.28% 46.80
2025 65.72 Est @ 4.56% 46.13
2026 67.93 Est @ 3.35% 44.94
2027 69.63 Est @ 2.5% 43.43
2028 70.96 Est @ 1.91% 41.72
2029 72.02 Est @ 1.5% 39.92
Present value of next 10 years cash flows DKK437.00
BATS-CHIXE:CHEMMC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= DKK72.02 × (1 + 0.53%) ÷ (6.08% – 0.53%)
DKK1,305.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= DKK1,305.00 ÷ (1 + 6.08%)10
DKK723.38
BATS-CHIXE:CHEMMC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= DKK437.00 + DKK723.38
DKK1,160.38
Equity Value per Share
(DKK)
= Total value / Shares Outstanding
= DKK1,160.38 / 15.75
DKK73.66
BATS-CHIXE:CHEMMC Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:CHEMMC represents 0.93033x of CPSE:CHEMM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93033x
Value per Share
(Listing Adjusted, DKK)
= Value per Share (DKK) x Listing Adjustment Factor
= DKK 73.66 x 0.93033
DKK68.53
Value per share (DKK) From above. DKK68.53
Current discount Discount to share price of DKK227.00
= -1 x (DKK227.00 - DKK68.53) / DKK68.53
-231.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of ChemoMetec is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ChemoMetec's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ChemoMetec's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:CHEMMC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in DKK DKK2.99
CPSE:CHEMM Share Price ** CPSE (2020-03-30) in DKK DKK244
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ChemoMetec.

BATS-CHIXE:CHEMMC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:CHEMM Share Price ÷ EPS (both in DKK)

= 244 ÷ 2.99

81.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChemoMetec is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • ChemoMetec is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does ChemoMetec's expected growth come at a high price?
Raw Data
BATS-CHIXE:CHEMMC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 81.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ChemoMetec, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ChemoMetec's assets?
Raw Data
BATS-CHIXE:CHEMMC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in DKK DKK25.22
CPSE:CHEMM Share Price * CPSE (2020-03-30) in DKK DKK244
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:CHEMMC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:CHEMM Share Price ÷ Book Value per Share (both in DKK)

= 244 ÷ 25.22

9.68x

* Primary Listing of ChemoMetec.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChemoMetec is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess ChemoMetec's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. ChemoMetec has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CHEMMC Future Performance

 How is ChemoMetec expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ChemoMetec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
43.5%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ChemoMetec expected to grow at an attractive rate?
  • Unable to compare ChemoMetec's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ChemoMetec's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare ChemoMetec's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:CHEMMC Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:CHEMMC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:CHEMMC Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2019-12-31 197 61 48
2019-09-30 186 60 45
2019-06-30 176 58 42
2019-03-31 158 50 37
2018-12-31 141 42 33
2018-09-30 127 34 25
2018-06-30 113 25 18
2018-03-31 107 20 15
2017-12-31 102 14 13
2017-09-30 96 12 10
2017-06-30 90 10 7
2017-03-31 88 13 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ChemoMetec is high growth as no earnings estimate data is available.
  • Unable to determine if ChemoMetec is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:CHEMMC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ChemoMetec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:CHEMMC Past Financials Data
Date (Data in DKK Millions) EPS *
2019-12-31 2.99
2019-09-30 2.84
2019-06-30 2.69
2019-03-31 2.40
2018-12-31 2.11
2018-09-30 1.64
2018-06-30 1.17
2018-03-31 0.98
2017-12-31 0.79
2017-09-30 0.64
2017-06-30 0.48
2017-03-31 0.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ChemoMetec will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Check out ChemoMetec's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
  2. ChemoMetec's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ChemoMetec's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ChemoMetec has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CHEMMC Past Performance

  How has ChemoMetec performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ChemoMetec's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ChemoMetec has delivered over 20% year on year earnings growth in the past 5 years.
  • ChemoMetec's 1-year earnings growth exceeds its 5-year average (47.6% vs 44.8%)
  • ChemoMetec's earnings growth has exceeded the Europe Life Sciences industry average in the past year (47.6% vs 6.3%).
Earnings and Revenue History
ChemoMetec's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ChemoMetec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:CHEMMC Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 196.90 47.98 101.32
2019-09-30 186.21 44.91 97.53
2019-06-30 175.51 41.85 93.73
2019-03-31 158.40 37.17 85.90
2018-12-31 141.28 32.50 78.06
2018-09-30 126.98 25.36 73.73
2018-06-30 112.69 18.22 69.40
2018-03-31 107.12 15.37 68.98
2017-12-31 101.55 12.53 68.57
2017-09-30 95.94 10.01 66.45
2017-06-30 90.33 7.49 64.33
2017-03-31 87.79 6.38 61.42
2016-12-31 85.26 5.27 58.50
2016-09-30 85.25 7.88 54.09
2016-06-30 85.23 10.48 49.67
2016-03-31 80.27 11.23 46.66
2015-12-31 75.31 11.98 43.64
2015-09-30 68.28 9.97 42.23
2015-06-30 61.24 7.95 40.83
2015-03-31 55.99 5.49 38.48
2014-12-31 50.75 3.03 36.14
2014-09-30 47.99 2.09 34.69
2014-06-30 45.23 1.15 33.25
2014-03-31 44.21 0.91 31.94
2013-12-31 43.20 0.68 30.64
2013-09-30 42.30 0.51 29.99
2013-06-30 41.40 0.35 29.34

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • ChemoMetec has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • ChemoMetec used its assets more efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • ChemoMetec has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess ChemoMetec's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ChemoMetec has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CHEMMC Health

 How is ChemoMetec's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ChemoMetec's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ChemoMetec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ChemoMetec's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ChemoMetec's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 263.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ChemoMetec Company Filings, last reported 3 months ago.

BATS-CHIXE:CHEMMC Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 397.27 1.59 291.32
2019-09-30 397.27 1.59 291.32
2019-06-30 173.34 18.80 98.20
2019-03-31 173.34 18.80 98.20
2018-12-31 84.42 19.00 11.07
2018-09-30 84.42 19.00 11.07
2018-06-30 73.01 19.21 9.78
2018-03-31 73.01 19.21 9.78
2017-12-31 66.41 22.96 9.01
2017-09-30 66.41 22.96 9.01
2017-06-30 64.38 20.57 12.40
2017-03-31 64.38 20.57 12.40
2016-12-31 58.72 20.74 9.51
2016-09-30 58.72 20.74 9.51
2016-06-30 56.85 20.70 14.12
2016-03-31 56.85 20.70 14.12
2015-12-31 53.51 21.15 6.33
2015-09-30 53.51 21.15 6.33
2015-06-30 46.35 6.92 10.89
2015-03-31 46.35 6.92 10.89
2014-12-31 41.64 0.00 4.32
2014-09-30 41.64 0.00 4.32
2014-06-30 44.53 0.00 6.85
2014-03-31 44.53 0.00 6.85
2013-12-31 44.67 0.00 8.12
2013-09-30 44.67 0.00 8.12
2013-06-30 43.23 0.00 9.07
  • ChemoMetec's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • ChemoMetec had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is well covered by operating cash flow (4525.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 42.4x coverage).
X
Financial health checks
We assess ChemoMetec's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ChemoMetec has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CHEMMC Dividends

 What is ChemoMetec's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.23%
Current annual income from ChemoMetec dividends.
If you bought DKK2,000 of ChemoMetec shares you are expected to receive DKK25 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • ChemoMetec's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.69%).
  • ChemoMetec's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.48%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:CHEMMC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:CHEMMC Past Annualized Dividends Data
Date (Data in DKK) Dividend per share (annual) Avg. Yield (%)
2019-09-17 3.000 1.467

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChemoMetec is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • ChemoMetec is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of ChemoMetec's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of ChemoMetec's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ChemoMetec's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ChemoMetec afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ChemoMetec has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CHEMMC Management

 What is the CEO of ChemoMetec's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steen Søndergaard
CEO Bio

Mr. Steen Søndergaard is a Chief Executive Officer at ChemoMetec A/S and served as its Chief Operating Officer & President.

CEO Compensation
  • Insufficient data for Steen to compare compensation growth.
  • Insufficient data for Steen to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Hans Glensbjerg

TITLE
Vice Chairman of the Board & COO
COMPENSATION
DKK20K

Steen Søndergaard

TITLE
Chief Executive Officer

Claus Madsen

TITLE
Chief Financial Officer

Lisbet Helles

TITLE
Marketing Manager

Søren Kjærulff

TITLE
Head of R&D

Nils Isbak

TITLE
Chief Commercial Officer

Michael Packert

TITLE
Head of Production
TENURE
0.7 yrs

Christopher Runchel

TITLE
Senior Vice President of US
TENURE
1.2 yrs
Board of Directors

Preben Kønig

TITLE
Chairman of the Board
COMPENSATION
DKK180K

Hans Glensbjerg

TITLE
Vice Chairman of the Board & COO
COMPENSATION
DKK20K
TENURE
5.6 yrs

Peter Reich

TITLE
Director
COMPENSATION
DKK40K
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (DKK) Value (DKK)
X
Management checks
We assess ChemoMetec's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ChemoMetec has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CHEMMC News

Simply Wall St News

CHEMMC Company Info

Description

ChemoMetec A/S designs, develops, and produces instruments for a range of applications in cell counting and evaluation in Denmark and internationally. The company offers automated cell counters and viability analyzers, such as NucleoCounter NC-3000, an advanced image cytometer to characterize cell properties; NucleoCounter NC-250, an automated cell analyzer to characterize cell properties; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determinations; NucleoCounter NC-100, a mammalian cell counter; NucleoCounter SP-100, a sperm cell counter that offers total sperm concentration and sperm viability in a semen sample from ejaculates or extended doses; NucleoCounter YC-100, a yeast cell counter used to measure the total cell count and viability of yeast cells in suspension; NucleoCounter SCC-100, a somatic cell counter for measuring the amount of somatic cells in a milk sample; and NucleoCounter SCC-400, a somatic cell counter for determining the number of somatic cells in a milk sample. It also provides Xcyto, a quantitative cell imager to analyze adherent and suspension cells; NucleoView, a software that is the user interface for the NucleoCounter NC-200, NC-250, and NC-3000 instruments, which automatically handles data acquisition, image analysis, and data presentation; consumables, which include cassettes, reagents, slides, and test kits; and accessories comprising cables, power supplies, software, and other products. The company offers its solutions for cell therapeutic, stem cell research, cancer cell research, bioprocessing, toxicology, cell biology research, sperm cell counting, yeast cell counting, and somatic cell counting applications. ChemoMetec A/S was founded in 1997 and is headquartered in Allerod, Denmark.

Details
Name: ChemoMetec A/S
CHEMMC
Exchange: BATS-CHIXE
Founded: 1997
DKK3,843,848,876
15,753,479
Website: http://www.chemometec.com
Address: ChemoMetec A/S
Gydevang 43,
Allerod,
Capital Region of Denmark, 3450,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE CHEMM Common Shares OMX Nordic Exchange Copenhagen DK DKK 18. Dec 2006
DB CHY Common Shares Deutsche Boerse AG DE EUR 18. Dec 2006
LSE 0DZ0 Common Shares London Stock Exchange GB DKK 18. Dec 2006
BATS-CHIXE CHEMMC Common Shares BATS 'Chi-X Europe' GB DKK 18. Dec 2006
Number of employees
Current staff
Staff numbers
0
ChemoMetec employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 20:06
End of day share price update: 2020/03/30 00:00
Last earnings filing: 2020/02/07
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.